Skip to main content

12.01.2024 | Rheumatologie | Originalien

Dos and Don’ts in der rheumatologischen Primärversorgung

verfasst von: Dr. med. univ. René Thonhofer, MBA

Erschienen in: rheuma plus

Einloggen, um Zugang zu erhalten

Zusammenfassung

Da die Ressourcen zur Versorgung von Patienten*Innen mit rheumatologischen Erkrankungen in einigen Regionen Österreichs limitiert sind, ist eine enge Zusammenarbeit von Ärzten*Innen der Primärversorgung mit Rheumatologen*Innen wichtig. Häufige, gut charakterisierte rheumatologische Erkrankungen, für die zusätzlich gut etablierte Therapieschemata bestehen (Arthritis urica, Polymyalgia rheumatica), können in der Primärversorgung, behandelt werden. Rheumatologen*Innen sollten bei komplexen oder atypischen Verläufen zugezogen werden. Auf die Bestimmung von Laborparametern, wie ANA, RF und HLA-B27, sollte ohne ausreichende Vortestwahrscheinlichkeit verzichtet werden, da hierdurch Kosten entstehen und Patienten*Innen einer oft nicht notwendigen rheumatologischen Abklärung zugeführt werden. Eine Glukokortikoidtherapie, bei Verdacht auf eine rheumatologische Erkrankung, ohne vorangegangene Diagnosestellung, sollte vermieden werden, da Symptome verschleiert werden und sich eine Diagnosestellung verzögern kann.
Literatur
1.
Zurück zum Zitat An J, Nyarko E, Hamad MA (2019) Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritis. Clin Rheumatol 38:2717–2726PubMedCrossRef An J, Nyarko E, Hamad MA (2019) Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritis. Clin Rheumatol 38:2717–2726PubMedCrossRef
2.
Zurück zum Zitat Geryk LL, Carpenter DM, Blalock SJ, DeVellis RF, Jordan JM (2015) The impact of co-morbidity on health-related quality of life in rheumatoid arthritis and osteoarthritis patients. Clin Exp Rheumatol 33:366–374PubMedPubMedCentral Geryk LL, Carpenter DM, Blalock SJ, DeVellis RF, Jordan JM (2015) The impact of co-morbidity on health-related quality of life in rheumatoid arthritis and osteoarthritis patients. Clin Exp Rheumatol 33:366–374PubMedPubMedCentral
3.
Zurück zum Zitat Smolen JS, Landewe RBM, Bergstra SA et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:3–18PubMedCrossRef Smolen JS, Landewe RBM, Bergstra SA et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:3–18PubMedCrossRef
4.
Zurück zum Zitat Drosos GC, Vedder D, Houben E et al (2022) EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 81:768–779PubMedCrossRef Drosos GC, Vedder D, Houben E et al (2022) EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 81:768–779PubMedCrossRef
5.
Zurück zum Zitat Dehlin M, Jacobsson L, Roddy E (2020) Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 16:380–390PubMedCrossRef Dehlin M, Jacobsson L, Roddy E (2020) Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 16:380–390PubMedCrossRef
6.
Zurück zum Zitat Elfishawi MM, Zleik N, Kvrgic Z et al (2018) The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years. J Rheumatol 45:574–579PubMedCrossRef Elfishawi MM, Zleik N, Kvrgic Z et al (2018) The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years. J Rheumatol 45:574–579PubMedCrossRef
7.
Zurück zum Zitat Bieber A, Schlesinger N, Fawaz A, Mader R (2018) Chronic tophaceous gout as the first manifestation of gout in two cases and a review of the literature. Semin Arthritis Rheum 47:843–848PubMedCrossRef Bieber A, Schlesinger N, Fawaz A, Mader R (2018) Chronic tophaceous gout as the first manifestation of gout in two cases and a review of the literature. Semin Arthritis Rheum 47:843–848PubMedCrossRef
8.
Zurück zum Zitat Dalbeth N, Gosling AL, Gaffo A, Abhishek A (2021) Gout. Lancet Dalbeth N, Gosling AL, Gaffo A, Abhishek A (2021) Gout. Lancet
9.
Zurück zum Zitat Richette P, Doherty M, Pascual E et al (2016) updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017(76):29–42 Richette P, Doherty M, Pascual E et al (2016) updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017(76):29–42
10.
Zurück zum Zitat Kannuthurai V, Gaffo A (2023) Management of patients with gout and kidney disease: a review of available therapies and common missteps. Kidney 4:e1332–e40CrossRef Kannuthurai V, Gaffo A (2023) Management of patients with gout and kidney disease: a review of available therapies and common missteps. Kidney 4:e1332–e40CrossRef
11.
Zurück zum Zitat Sautner J, Eichbauer-Sturm G, Gruber J, Lunzer R, Puchner R (2022) Update of the Austrian Society for Rheumatology and Rehabilitation nutrition and lifestyle recommendations for patients with gout and hyperuricemia. Z Rheumatol 2023(82):71–81 Sautner J, Eichbauer-Sturm G, Gruber J, Lunzer R, Puchner R (2022) Update of the Austrian Society for Rheumatology and Rehabilitation nutrition and lifestyle recommendations for patients with gout and hyperuricemia. Z Rheumatol 2023(82):71–81
13.
Zurück zum Zitat Schlesinger N, Perez-Ruiz F, Liote F (2023) Mechanisms and rationale for uricase use in patients with gout. Nat Rev Rheumatol Schlesinger N, Perez-Ruiz F, Liote F (2023) Mechanisms and rationale for uricase use in patients with gout. Nat Rev Rheumatol
14.
Zurück zum Zitat Schlesinger N, Pillinger MH, Simon LS, Lipsky PE (2023) Interleukin-1beta inhibitors for the management of acute gout flares: a systematic literature review. Arthritis Res Ther 25:128PubMedPubMedCentralCrossRef Schlesinger N, Pillinger MH, Simon LS, Lipsky PE (2023) Interleukin-1beta inhibitors for the management of acute gout flares: a systematic literature review. Arthritis Res Ther 25:128PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Raheel S, Shbeeb I, Crowson CS, Matteson EL (2017) Epidemiology of polymyalgia rheumatica 2000–2014 and examination of incidence and survival trends over 45 years: a population-based study. Arthritis Care Res 69:1282–1285CrossRef Raheel S, Shbeeb I, Crowson CS, Matteson EL (2017) Epidemiology of polymyalgia rheumatica 2000–2014 and examination of incidence and survival trends over 45 years: a population-based study. Arthritis Care Res 69:1282–1285CrossRef
16.
Zurück zum Zitat Camellino D, Giusti A, Girasole G, Bianchi G, Dejaco C (2019) Pathogenesis, diagnosis and management of polymyalgia rheumatica. Drugs Aging 36:1015–1026PubMedCrossRef Camellino D, Giusti A, Girasole G, Bianchi G, Dejaco C (2019) Pathogenesis, diagnosis and management of polymyalgia rheumatica. Drugs Aging 36:1015–1026PubMedCrossRef
17.
Zurück zum Zitat Dejaco C, Kerschbaumer A, Aletaha D et al (2023) Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis Dejaco C, Kerschbaumer A, Aletaha D et al (2023) Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis
18.
Zurück zum Zitat Buttgereit F, Matteson EL, Dejaco C (2020) Polymyalgia rheumatica and giant cell arteritis. JAMA 324:993–994PubMedCrossRef Buttgereit F, Matteson EL, Dejaco C (2020) Polymyalgia rheumatica and giant cell arteritis. JAMA 324:993–994PubMedCrossRef
19.
Zurück zum Zitat Dougados M, Soubrier M, Antunez A et al (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62–68PubMedCrossRef Dougados M, Soubrier M, Antunez A et al (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62–68PubMedCrossRef
20.
Zurück zum Zitat Furer V, Rondaan C, Heijstek M et al (2019) Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open 5:e1041PubMedPubMedCentralCrossRef Furer V, Rondaan C, Heijstek M et al (2019) Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open 5:e1041PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Blumentals WA, Arreglado A, Napalkov P, Toovey S (2012) Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord 13:158PubMedPubMedCentralCrossRef Blumentals WA, Arreglado A, Napalkov P, Toovey S (2012) Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord 13:158PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603–2615PubMedCrossRef Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603–2615PubMedCrossRef
23.
Zurück zum Zitat Furer V, Rondaan C, Heijstek MW et al (2019) update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020(79):39–52 Furer V, Rondaan C, Heijstek MW et al (2019) update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020(79):39–52
24.
Zurück zum Zitat Specker C, Aries P, Braun J et al (2021) Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination. Z Rheumatol 80:33–48PubMedPubMedCentralCrossRef Specker C, Aries P, Braun J et al (2021) Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination. Z Rheumatol 80:33–48PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Feuchtenberger M, Kleinert S, Schwab S et al (2012) Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study. Rheumatol Int 32:1533–1539PubMedCrossRef Feuchtenberger M, Kleinert S, Schwab S et al (2012) Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study. Rheumatol Int 32:1533–1539PubMedCrossRef
26.
Zurück zum Zitat Murray K, Low C, O’Rourke A et al (2020) A quality improvement intervention failed to significantly increase pneumococcal and influenza vaccination rates in immunosuppressed inflammatory arthritis patients. Clin Rheumatol 39:747–754PubMedCrossRef Murray K, Low C, O’Rourke A et al (2020) A quality improvement intervention failed to significantly increase pneumococcal and influenza vaccination rates in immunosuppressed inflammatory arthritis patients. Clin Rheumatol 39:747–754PubMedCrossRef
27.
Zurück zum Zitat Strnad M, Honig V, Ruzek D, Grubhoffer L, Rego ROM (2017) Europe-wide meta-analysis of borrelia burgdorferi sensu lato prevalence in questing Ixodes ricinus ticks. Appl Environ Microbiol 83: Strnad M, Honig V, Ruzek D, Grubhoffer L, Rego ROM (2017) Europe-wide meta-analysis of borrelia burgdorferi sensu lato prevalence in questing Ixodes ricinus ticks. Appl Environ Microbiol 83:
28.
Zurück zum Zitat Estrada-Pena A, Cutler S, Potkonjak A et al (2018) An updated meta-analysis of the distribution and prevalence of Borrelia burgdorferi s. l. in ticks in Europe. Int J Health Geogr 17:41PubMedPubMedCentralCrossRef Estrada-Pena A, Cutler S, Potkonjak A et al (2018) An updated meta-analysis of the distribution and prevalence of Borrelia burgdorferi s. l. in ticks in Europe. Int J Health Geogr 17:41PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Radolf JD, Strle K, Lemieux JE, Strle F (2021) Lyme disease in humans. Curr Issues Mol Biol 42:333–384PubMed Radolf JD, Strle K, Lemieux JE, Strle F (2021) Lyme disease in humans. Curr Issues Mol Biol 42:333–384PubMed
30.
Zurück zum Zitat Steere AC, Schoen RT, Taylor E (1987) The clinical evolution of lyme arthritis. Ann Intern Med 107:725–731PubMedCrossRef Steere AC, Schoen RT, Taylor E (1987) The clinical evolution of lyme arthritis. Ann Intern Med 107:725–731PubMedCrossRef
31.
Zurück zum Zitat Deanehan JK, Kimia AA, Tan Tanny SP et al (2013) Distinguishing lyme from septic knee monoarthritis in lyme disease-endemic areas. Pediatrics 131:e695–701PubMedCrossRef Deanehan JK, Kimia AA, Tan Tanny SP et al (2013) Distinguishing lyme from septic knee monoarthritis in lyme disease-endemic areas. Pediatrics 131:e695–701PubMedCrossRef
33.
Zurück zum Zitat Stanek G, Strle F (2018) Lyme borreliosis-from tick bite to diagnosis and treatment. FEMS Microbiol Rev 42:233–258PubMedCrossRef Stanek G, Strle F (2018) Lyme borreliosis-from tick bite to diagnosis and treatment. FEMS Microbiol Rev 42:233–258PubMedCrossRef
34.
Zurück zum Zitat Muller I, Freitag MH, Poggensee G et al (2012) Evaluating frequency, diagnostic quality, and cost of Lyme borreliosis testing in Germany: a retrospective model analysis. Clin Dev Immunol 2012:595427PubMedCrossRef Muller I, Freitag MH, Poggensee G et al (2012) Evaluating frequency, diagnostic quality, and cost of Lyme borreliosis testing in Germany: a retrospective model analysis. Clin Dev Immunol 2012:595427PubMedCrossRef
35.
Zurück zum Zitat Wormser GP, Schriefer M, Aguero-Rosenfeld ME et al (2013) Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for lyme disease. Diagn Microbiol Infect Dis 75:9–15PubMedCrossRef Wormser GP, Schriefer M, Aguero-Rosenfeld ME et al (2013) Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for lyme disease. Diagn Microbiol Infect Dis 75:9–15PubMedCrossRef
36.
Zurück zum Zitat Seriburi V, Ndukwe N, Chang Z, Cox ME, Wormser GP (2012) High frequency of false positive IgM immunoblots for Borrelia burgdorferi in clinical practice. Clin Microbiol Infect 18:1236–1240PubMedCrossRef Seriburi V, Ndukwe N, Chang Z, Cox ME, Wormser GP (2012) High frequency of false positive IgM immunoblots for Borrelia burgdorferi in clinical practice. Clin Microbiol Infect 18:1236–1240PubMedCrossRef
37.
Zurück zum Zitat Jaulhac B, Saunier A, Caumes E et al (2019) Lyme borreliosis and other tick-borne diseases. Guidelines from the French scientific societies (II). Biological diagnosis, treatment, persistent symptoms after documented or suspected Lyme borreliosis. Med Mal Infect 49:335–346PubMedCrossRef Jaulhac B, Saunier A, Caumes E et al (2019) Lyme borreliosis and other tick-borne diseases. Guidelines from the French scientific societies (II). Biological diagnosis, treatment, persistent symptoms after documented or suspected Lyme borreliosis. Med Mal Infect 49:335–346PubMedCrossRef
38.
Zurück zum Zitat Fallon BA, Pavlicova M, Coffino SW, Brenner C (2014) A comparison of lyme disease serologic test results from 4 laboratories in patients with persistent symptoms after antibiotic treatment. Clin Infect Dis 59:1705–1710PubMedCrossRef Fallon BA, Pavlicova M, Coffino SW, Brenner C (2014) A comparison of lyme disease serologic test results from 4 laboratories in patients with persistent symptoms after antibiotic treatment. Clin Infect Dis 59:1705–1710PubMedCrossRef
39.
Zurück zum Zitat Lantos PM, Rumbaugh J, Bockenstedt LK et al (2021) Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis and treatment of lyme disease. Clin Infect Dis 72:1–8PubMedCrossRef Lantos PM, Rumbaugh J, Bockenstedt LK et al (2021) Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis and treatment of lyme disease. Clin Infect Dis 72:1–8PubMedCrossRef
40.
Zurück zum Zitat Visser H, Gelinck LB, Kampfraath AH, Breedveld FC, Hazes JM (1996) Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 55:157–161PubMedPubMedCentralCrossRef Visser H, Gelinck LB, Kampfraath AH, Breedveld FC, Hazes JM (1996) Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 55:157–161PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Dinse GE, Parks CG, Weinberg CR et al (2020) Increasing prevalence of antinuclear antibodies in the United States. Arthritis Rheumatol 72:1026–1035PubMedPubMedCentralCrossRef Dinse GE, Parks CG, Weinberg CR et al (2020) Increasing prevalence of antinuclear antibodies in the United States. Arthritis Rheumatol 72:1026–1035PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Chan EK, Damoiseaux J, Carballo OG et al (2015) Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp‑2 cell patterns 2014–2015. Front Immunol 6:412PubMedPubMedCentralCrossRef Chan EK, Damoiseaux J, Carballo OG et al (2015) Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp‑2 cell patterns 2014–2015. Front Immunol 6:412PubMedPubMedCentralCrossRef
44.
45.
Zurück zum Zitat Damoiseaux J, Andrade LEC, Carballo OG et al (2019) Clinical relevance of HEp‑2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis 78:879–889PubMedCrossRef Damoiseaux J, Andrade LEC, Carballo OG et al (2019) Clinical relevance of HEp‑2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis 78:879–889PubMedCrossRef
46.
Zurück zum Zitat Abeles AM, Abeles M (2013) The clinical utility of a positive antinuclear antibody test result. Am J Med 126:342–348PubMedCrossRef Abeles AM, Abeles M (2013) The clinical utility of a positive antinuclear antibody test result. Am J Med 126:342–348PubMedCrossRef
47.
Zurück zum Zitat Fitch-Rogalsky C, Steber W, Mahler M et al (2014) Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. PLoS One 9:e93812PubMedPubMedCentralCrossRef Fitch-Rogalsky C, Steber W, Mahler M et al (2014) Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. PLoS One 9:e93812PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Ruta S, Prado ES, Chichande JT et al (2020) EULAR definition of „arthralgia suspicious for progression to rheumatoid arthritis“ in a large cohort of patients included in a program for rapid diagnosis: role of auto-antibodies and ultrasound. Clin Rheumatol 39:1493–1499PubMedCrossRef Ruta S, Prado ES, Chichande JT et al (2020) EULAR definition of „arthralgia suspicious for progression to rheumatoid arthritis“ in a large cohort of patients included in a program for rapid diagnosis: role of auto-antibodies and ultrasound. Clin Rheumatol 39:1493–1499PubMedCrossRef
49.
Zurück zum Zitat Morsley K, Miller A, Luqmani R et al (2019) Rheumatoid factor testing in Spanish primary care: a population-based cohort study including 4.8 million subjects and almost half a million measurements. Reumatol Clin 15:350–354PubMedCrossRef Morsley K, Miller A, Luqmani R et al (2019) Rheumatoid factor testing in Spanish primary care: a population-based cohort study including 4.8 million subjects and almost half a million measurements. Reumatol Clin 15:350–354PubMedCrossRef
50.
Zurück zum Zitat Miller A, Mahtani KR, Waterfield MA, Timms A, Misbah SA, Luqmani RA (2013) Is rheumatoid factor useful in primary care? A retrospective cross-sectional study. Clin Rheumatol 32:1089–1093PubMedCrossRef Miller A, Mahtani KR, Waterfield MA, Timms A, Misbah SA, Luqmani RA (2013) Is rheumatoid factor useful in primary care? A retrospective cross-sectional study. Clin Rheumatol 32:1089–1093PubMedCrossRef
52.
Zurück zum Zitat Lin H, Gong YZ (2017) Association of HLA-B27 with ankylosing spondylitis and clinical features of the HLA-B27-associated ankylosing spondylitis: a meta-analysis. Rheumatol Int 37:1267–1280PubMedCrossRef Lin H, Gong YZ (2017) Association of HLA-B27 with ankylosing spondylitis and clinical features of the HLA-B27-associated ankylosing spondylitis: a meta-analysis. Rheumatol Int 37:1267–1280PubMedCrossRef
53.
Zurück zum Zitat Poddubnyy D (2020) Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis. Rheumatology 59:iv6:iv17 Poddubnyy D (2020) Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis. Rheumatology 59:iv6:iv17
54.
Zurück zum Zitat Weisman MH, Witter JP, Reveille JD (2013) The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009–10. Ann Rheum Dis 72:369–373PubMedCrossRef Weisman MH, Witter JP, Reveille JD (2013) The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009–10. Ann Rheum Dis 72:369–373PubMedCrossRef
55.
Zurück zum Zitat Underwood MR, Dawes P (1995) Inflammatory back pain in primary care. Br J Rheumatol 34:1074–1077PubMedCrossRef Underwood MR, Dawes P (1995) Inflammatory back pain in primary care. Br J Rheumatol 34:1074–1077PubMedCrossRef
56.
Zurück zum Zitat Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J (2004) How to diagnose axial spondyloarthritis early. Ann Rheum Dis 63:535–543PubMedPubMedCentralCrossRef Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J (2004) How to diagnose axial spondyloarthritis early. Ann Rheum Dis 63:535–543PubMedPubMedCentralCrossRef
57.
Zurück zum Zitat Hellmich B, Sanchez-Alamo B, Schirmer JH et al (2023) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis Hellmich B, Sanchez-Alamo B, Schirmer JH et al (2023) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis
Metadaten
Titel
Dos and Don’ts in der rheumatologischen Primärversorgung
verfasst von
Dr. med. univ. René Thonhofer, MBA
Publikationsdatum
12.01.2024
Verlag
Springer Vienna
Erschienen in
rheuma plus
Print ISSN: 1868-260X
Elektronische ISSN: 2191-2610
DOI
https://doi.org/10.1007/s12688-023-00698-5